Alzheimer's Disease Treatments
The UCLA Amyloid Immunotherapy Care Program
The UCLA Amyloid Immunotherapy Care (AIC) Program is at the forefront of Alzheimer’s disease to target amyloid-beta plaques. The program is to advance the development of effective immunotherapies that could potentially slow or halt Alzheimer's progression.
Learn more about the AIC Program
Lecanemab
The FDA approved lecanemab under accelerated approval based on reduction in amyloid plaques in patients treated with this medication in clinical trials. It is delivered as infusions every two weeks. The FDA decision on full approval of lecanemab is pending.